Voquezna Triple Pak Patent Expiration

Voquezna Triple Pak is a drug owned by Phathom Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2022 out of which none have expired yet. Voquezna Triple Pak's patents will be open to challenges from 04 May, 2031. Based on its patents and exclusivities, its generic launch date is estimated to be May 03, 2032. Details of Voquezna Triple Pak's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US7977488 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(3 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 Pharmaceutical composition
Aug, 2030

(5 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Voquezna Triple Pak's patents.

Given below is the list of recent legal activities going on the following patents of Voquezna Triple Pak.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 01 Mar, 2024 US7977488
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US7977488
Initial letter Re: PTE Application to regulating agency 17 Aug, 2023 US7977488
Change in Power of Attorney (May Include Associate POA) 16 Jun, 2023 US9186411
Email Notification 16 Jun, 2023 US9186411
Payment of Maintenance Fee, 8th Year, Large Entity 20 Apr, 2023 US9186411
Payment of Maintenance Fee, 12th Year, Large Entity 20 Dec, 2022 US7977488
Change in Power of Attorney (May Include Associate POA) 13 Jul, 2022 US7977488
Email Notification 13 Jul, 2022 US7977488
Correspondence Address Change 12 Jul, 2022 US7977488


FDA has granted several exclusivities to Voquezna Triple Pak. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Voquezna Triple Pak, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Voquezna Triple Pak.

Exclusivity Information

Voquezna Triple Pak holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2032. Details of Voquezna Triple Pak's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 03, 2027
Generating Antibiotic Incentives Now(GAIN) May 03, 2032

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Voquezna Triple Pak is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Voquezna Triple Pak's family patents as well as insights into ongoing legal events on those patents.

Voquezna Triple Pak's Family Patents

Voquezna Triple Pak has patent protection in a total of 43 countries. It's US patent count contributes only to 10.3% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Voquezna Triple Pak.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Voquezna Triple Pak's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 03, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Voquezna Triple Pak Generics:

There are no approved generic versions for Voquezna Triple Pak as of now.





About Voquezna Triple Pak

Voquezna Triple Pak is a drug owned by Phathom Pharmaceuticals Inc. Voquezna Triple Pak uses Amoxicillin; Clarithromycin; Vonoprazan Fumarate as an active ingredient. Voquezna Triple Pak was launched by Phathom in 2022.

Approval Date:

Voquezna Triple Pak was approved by FDA for market use on 03 May, 2022.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Voquezna Triple Pak is 03 May, 2022, its NCE-1 date is estimated to be 04 May, 2031.

Active Ingredient:

Voquezna Triple Pak uses Amoxicillin; Clarithromycin; Vonoprazan Fumarate as the active ingredient. Check out other Drugs and Companies using Amoxicillin; Clarithromycin; Vonoprazan Fumarate ingredient

Dosage:

Voquezna Triple Pak is available in capsule, tablet, tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500MG;500MG;EQ 20MG BASE CAPSULE, TABLET, TABLET Prescription ORAL